Bladder cancer

Filippo De Braud, Massimo Maffezzini, Vito Vitale, Paolo Bruzzi, Gemma Gatta, William F. Hendry, Cora N. Sternberg

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bladder cancer two- to fivefold as well as the exposure to metabolites of aniline dyes and other aromatic amines. Seventy-five per cent of bladder cancers are superficial at initial presentation, limited to the mucosa, submucosa, or lamina propria. Recurrence rates after initial treatment are 50-80%, with progression to muscle-invading tumour in 10-25%. In muscle-invading bladder cancers, there is a 50% risk of distant metastases. Surgery is the mainstay of standard treatment both in the form of transurethral endoscopic resection, mainly for superficial disease, and in the form of open ablative surgery with urinary diversion for muscle invasive disease. Endovesical administration of BCG has been employed after endoscopic resection as the most effective agent for both prophylaxis of disease recurrence and progression from superficial to invasive disease. The accepted treatment for muscle infiltrative disease is radical cystectomy. Response rates to combination chemotherapy regimens of up to 70% in patients with advanced metastatic disease have led to an investigation of its use for locally invasive disease in combination with conventional modalities of treatment.

Original languageEnglish
Pages (from-to)89-106
Number of pages18
JournalCritical Reviews in Oncology/Hematology
Volume41
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Urinary Bladder Neoplasms
Muscles
Mucous Membrane
Recurrence
Urinary Diversion
Cystectomy
Therapeutics
Mycobacterium bovis
Combination Drug Therapy
Smoke
Tobacco
Amines
Disease Progression
Neoplasms
Coloring Agents
Neoplasm Metastasis

Keywords

  • Bladder cancer
  • Carcinogens
  • Urogenital tract

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

De Braud, F., Maffezzini, M., Vitale, V., Bruzzi, P., Gatta, G., Hendry, W. F., & Sternberg, C. N. (2002). Bladder cancer. Critical Reviews in Oncology/Hematology, 41(1), 89-106. https://doi.org/10.1016/S1040-8428(01)00128-7

Bladder cancer. / De Braud, Filippo; Maffezzini, Massimo; Vitale, Vito; Bruzzi, Paolo; Gatta, Gemma; Hendry, William F.; Sternberg, Cora N.

In: Critical Reviews in Oncology/Hematology, Vol. 41, No. 1, 2002, p. 89-106.

Research output: Contribution to journalArticle

De Braud, F, Maffezzini, M, Vitale, V, Bruzzi, P, Gatta, G, Hendry, WF & Sternberg, CN 2002, 'Bladder cancer', Critical Reviews in Oncology/Hematology, vol. 41, no. 1, pp. 89-106. https://doi.org/10.1016/S1040-8428(01)00128-7
De Braud, Filippo ; Maffezzini, Massimo ; Vitale, Vito ; Bruzzi, Paolo ; Gatta, Gemma ; Hendry, William F. ; Sternberg, Cora N. / Bladder cancer. In: Critical Reviews in Oncology/Hematology. 2002 ; Vol. 41, No. 1. pp. 89-106.
@article{8f8787942c5b4f82b68b918e0f45cd7d,
title = "Bladder cancer",
abstract = "Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bladder cancer two- to fivefold as well as the exposure to metabolites of aniline dyes and other aromatic amines. Seventy-five per cent of bladder cancers are superficial at initial presentation, limited to the mucosa, submucosa, or lamina propria. Recurrence rates after initial treatment are 50-80{\%}, with progression to muscle-invading tumour in 10-25{\%}. In muscle-invading bladder cancers, there is a 50{\%} risk of distant metastases. Surgery is the mainstay of standard treatment both in the form of transurethral endoscopic resection, mainly for superficial disease, and in the form of open ablative surgery with urinary diversion for muscle invasive disease. Endovesical administration of BCG has been employed after endoscopic resection as the most effective agent for both prophylaxis of disease recurrence and progression from superficial to invasive disease. The accepted treatment for muscle infiltrative disease is radical cystectomy. Response rates to combination chemotherapy regimens of up to 70{\%} in patients with advanced metastatic disease have led to an investigation of its use for locally invasive disease in combination with conventional modalities of treatment.",
keywords = "Bladder cancer, Carcinogens, Urogenital tract",
author = "{De Braud}, Filippo and Massimo Maffezzini and Vito Vitale and Paolo Bruzzi and Gemma Gatta and Hendry, {William F.} and Sternberg, {Cora N.}",
year = "2002",
doi = "10.1016/S1040-8428(01)00128-7",
language = "English",
volume = "41",
pages = "89--106",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Bladder cancer

AU - De Braud, Filippo

AU - Maffezzini, Massimo

AU - Vitale, Vito

AU - Bruzzi, Paolo

AU - Gatta, Gemma

AU - Hendry, William F.

AU - Sternberg, Cora N.

PY - 2002

Y1 - 2002

N2 - Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bladder cancer two- to fivefold as well as the exposure to metabolites of aniline dyes and other aromatic amines. Seventy-five per cent of bladder cancers are superficial at initial presentation, limited to the mucosa, submucosa, or lamina propria. Recurrence rates after initial treatment are 50-80%, with progression to muscle-invading tumour in 10-25%. In muscle-invading bladder cancers, there is a 50% risk of distant metastases. Surgery is the mainstay of standard treatment both in the form of transurethral endoscopic resection, mainly for superficial disease, and in the form of open ablative surgery with urinary diversion for muscle invasive disease. Endovesical administration of BCG has been employed after endoscopic resection as the most effective agent for both prophylaxis of disease recurrence and progression from superficial to invasive disease. The accepted treatment for muscle infiltrative disease is radical cystectomy. Response rates to combination chemotherapy regimens of up to 70% in patients with advanced metastatic disease have led to an investigation of its use for locally invasive disease in combination with conventional modalities of treatment.

AB - Bladder cancer is the second most frequent tumour of the urogenital tract. Tobacco smoke has been shown to increase the risk of bladder cancer two- to fivefold as well as the exposure to metabolites of aniline dyes and other aromatic amines. Seventy-five per cent of bladder cancers are superficial at initial presentation, limited to the mucosa, submucosa, or lamina propria. Recurrence rates after initial treatment are 50-80%, with progression to muscle-invading tumour in 10-25%. In muscle-invading bladder cancers, there is a 50% risk of distant metastases. Surgery is the mainstay of standard treatment both in the form of transurethral endoscopic resection, mainly for superficial disease, and in the form of open ablative surgery with urinary diversion for muscle invasive disease. Endovesical administration of BCG has been employed after endoscopic resection as the most effective agent for both prophylaxis of disease recurrence and progression from superficial to invasive disease. The accepted treatment for muscle infiltrative disease is radical cystectomy. Response rates to combination chemotherapy regimens of up to 70% in patients with advanced metastatic disease have led to an investigation of its use for locally invasive disease in combination with conventional modalities of treatment.

KW - Bladder cancer

KW - Carcinogens

KW - Urogenital tract

UR - http://www.scopus.com/inward/record.url?scp=0036142313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036142313&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(01)00128-7

DO - 10.1016/S1040-8428(01)00128-7

M3 - Article

VL - 41

SP - 89

EP - 106

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -